Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus chemotherapy with or without bevacizumab in cervical cancer
NCT04982237Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in Cervical Cancer (CC), sponsored by Akeso, Inc.. Started Aug 2021; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04982237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982237.